SCHEMBL2029600

SCHEMBL2029600

O=C1NC(=O)C(=Cc2cnn3c(NC4CC4)nc(Nc4cccc(Cl)c4)nc23)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 5/20 0.47
CSNK2B P67870 3/20 0.47
PAK4 O96013 2/20 0.39
CTSV O60911 1/20 0.38
PLAT P00750 1/20 0.38
CTSL P07711 1/20 0.38
CTSH P09668 1/20 0.38
CTSS P25774 1/20 0.38
CASP14 P31944 1/20 0.38
CTSK P43235 1/20 0.38
CASP6 P55212 1/20 0.38
CTSZ Q9UBR2 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
HSP90AA1 P07900 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029594 1.00 CSNK2A1 (0.47) CSNK2A1CSNK2BPAK4CTSVPLAT
SCHEMBL2029597 1.00 CSNK2A1 (0.47) CSNK2A1CSNK2BPAK4CTSVPLAT
SCHEMBL14242560 0.90 CSNK2A1 (0.51) CSNK2A1CSNK2BKDM4ECYP3A4MAPT
SCHEMBL12645238 0.90 CSNK2A1 (0.47) CSNK2A1CSNK2BPAK4CTSLCTSS
SCHEMBL12644713 0.88 MAPKAPK2 (0.42) CSNK2A1CSNK2BHPGDCDK1EGFR
SCHEMBL12645246 0.88 CSNK2A1 (0.46) CSNK2A1CSNK2BKDM4EMEN1POLB
SCHEMBL12645639 0.88 CSNK2A1 (0.46) CSNK2A1CDK1PRKDC
SCHEMBL12644827 0.88 CSNK2A1 (0.51) CSNK2A1CSNK2BCTSLCTSSCTSK
SCHEMBL12644694 0.88 CSNK2A1 (0.47) CSNK2A1CTSLCTSSCTSKMEN1
SCHEMBL12645258 0.87 CSNK2A1 (0.42) CSNK2A1CSNK2BKDM4ECYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509602-B9 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-11-01 EP disclosed
EP-2509602-B1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-01-25 EP disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CDK2, CKS2, CSNK2A1 CSNK2A1 3/4885CSNK2B 13/4885PAK4 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.